Cycloalkylamine derivatives as NK-1/SSRI antagonists
The present disclosure relates to chemical compounds and their use in human therapy. A specific embodiment relates to compounds of Formula (I) or an isomer, a pharmaceutically acceptable salt or solvate thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors.
1. A compound of Formula (I)
or an isomer, a pharmaceutically acceptable salt thereof wherein
R 1 , R 2 , R 3 , R 4 , R 5 and R 6 independently are hydrogen, C 1-4 alkyl, C 1-4 alkoxy, fluoroC 1-4 alkyl, halogen or cyano;
X is O;
R 7 is hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl or C 3-6 cycloalkylC 1-3 alkyl;
R 8 is hydrogen or C 1-4 alkyl;
r is 2 and s is 4 or r is 3 and s is 3.
2. The compound of claim 1 , wherein R 7 is hydrogen.
3. The compound of claim 1 wherein R 4 and R 5 are each independently CF 3 and R 6 is hydrogen.
4. The compound of claim 2 wherein R 4 and R 5 are each independently CF 3 and R 6 is hydrogen.
5. The compound of claim 1 wherein r is 2 and s is 4.
6. The compound of claim 1 wherein r is 3 and s is 3.
7. The pharmaceutical composition comprising a compound of claim 1 , together with at least one pharmaceutically acceptable excipient.